Table 33Summary of embolization treatment study characteristics: RCTs

Study
N
Rating
InterventionIntervention PeriodMean Age
(Range)
CP
A%; B%
BCLC
A%; B%
Previous LDT %
Malagari et al. 201061
84
Poor
Transarterial DEB with DC beads® loaded with doxorubicin (37.5 mg/mL of bead suspension) every 2 months with a maximum of 3 procedures200570.7
(NR)
A: 56.1;
B: 43.9
NRNR
Bland embolization with nonloaded particles of the same diameter and mechanics as DEB (BeadBlock) every 2 months with a maximum of 3 procedures200570.0
(NR)
A: 60.5;
B: 39.5
NRNR
Sacco et al. 201162
67
Fair
TACE with iodized oil (mean: 16.6 mL, range: 10–25 mL), doxorubicin (mean: 57.0 mg, range: 50–75 mg) and gelatin sponge particles via hepatic arteries01/2006 - 03/200968.7
(NR)
A: 73.5;
B: 26.5
A: 64.7;
B: 35.3
NR
DEB chemoembolization with DC Bead® (2-4 mL, 100–300 μm) loaded with doxorubicin (50 mg/vial, mean: 55 mg, range: 25–150 mg) mixed with nonionic contrast medium at a 1:3 ratio via superselective injection01/2006 - 03/200971.3
(NR)
A: 87.9;
B: 12.1
A: 66.7;
B: 33.3
NR

Abbreviations: BCLC = Barcelona Clinic Liver Center hepatocellular carcinoma stage; CP = Child-Pugh liver cirrhosis class; DEB = drug-eluting bead; LDT = liver-directed therapy; N = number of patients; NR = not reported; TACE = transarterial chemoembolization.

From: Results

Cover of Local Therapies for Unresectable Primary Hepatocellular Carcinoma
Local Therapies for Unresectable Primary Hepatocellular Carcinoma [Internet].
Comparative Effectiveness Reviews, No. 114.
Belinson S, Yang Y, Chopra R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.